Friday, 15 Dec 2017

You are here

Anti-Sclerostin Drug Hampered by Heart Problems

Reuters reports that FDA approval of romosozumab (brand name Evenity) may be held up because of higher rates of cardiac events seen in a late-stage clinical trial.

Romosozumab is being codeveloped by Amgen and UCB who have released top-line results of the ARCH trial, a successful study in postmenopausal women with osteoporosis (OP).

Patients in the study received romosozumab for 12 months followed by alendronate, versus those on alendronate alone. Romosozumab was shown to significantly reduce vertebral and non-vertebral fractures through 24 months compared to alendronate.

However, an imbalance of serious heart problems were reported; 2.5 percent on romosozumab versus 1.9 in the alendronate group. Interestingly, no increased risk of cardiac events was seen in another pivotal trial, the placebo-controlled FRAME study (n=7180-patients). The company reports that other adverse events were equal between groups. 

"The efficacy results from this study comparing Evenity to an active control are robust. At the same time, the newly observed cardiovascular safety signal will have to be assessed as part of the overall benefit/risk profile for Evenity," Amgen research chief Sean Harper said.

These findings are thought to create significant obstacles for bringing this drug to market in 2017.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Knee Surgery Outcomes Worse with Low Education

Reuters reports that patients who live in low-income communities and lack a college education may have worse pain after knee replacement surgery than their more educated neighbors, citing results from a recent study from the Hospital for Special Surgery in NY.

Weight Loss Does Not Protect OA Knees

A new study presented at the Radiological Society of North America (RSNA) shows that obese people with substantial weight loss may significantly slow down the rate of joint space narrowing (cartilage degeneration) in the knee cartilage, but only if they lose weight through diet and exercise or diet alone; excercise alone is insufficient. 

Prevalence of Arthritis Grossly Underestimated

Researchers at the Boston University School of Medicine have published a new report showing that arthritis affected 91 million adults in the US in 2015 or 37% of the poplulation. Their prevalence estimate is 68% higher than previously reported arthritis national estimates. 

Zilretta - a New Drug FDA Approved for Osteoarthritis of the Knee

Flexion Therapeutics announced friday that the U.S. Food and Drug Administration (FDA) has approved its osteoarthritis (OA) of the knee injectable steroid drug Zilretta with the indication of moderate-to-severe knee pain.

Zilretta is the commonly used triamcinolon acetonide combined with a drug delivery system designed to provide extended pain relief over three months.

UAB Researchers Shed Light on Age-Related Osteoporosis

Researchers from the University of Alabama at Birmingham (UAB) have detailed mechanisms leading to age-related bone loss and osteoporosis.